Unicycive Therapeutics Stock Z Score

UNCY Stock  USD 1.14  0.08  6.56%   
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Unicycive Therapeutics Piotroski F Score and Unicycive Therapeutics Valuation analysis.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.
  
At this time, Unicycive Therapeutics' Capital Lease Obligations is fairly stable compared to the past year. Capital Expenditures is likely to rise to about 17.3 K in 2024, despite the fact that Net Invested Capital is likely to grow to (3.6 M). At this time, Unicycive Therapeutics' Net Interest Income is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 386.4 K in 2024, whereas Interest Expense is likely to drop slightly above 77.9 K in 2024.

Unicycive Therapeutics Company Z Score Analysis

Unicycive Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

 = 

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

 = 

1.2 * (

Working Capital

/

Total Assets )

Second Factor

 = 

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

 = 

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

 = 

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

 = 

0.99 * (

Revenue

/

Total Assets )

Unicycive Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Unicycive Therapeutics is extremely important. It helps to project a fair market value of Unicycive Stock properly, considering its historical fundamentals such as Z Score. Since Unicycive Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Unicycive Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Unicycive Therapeutics' interrelated accounts and indicators.
-0.910.930.88-0.30.830.25-0.810.770.19-0.510.820.23-0.3-0.68-0.68
-0.91-0.81-0.750.18-0.660.150.62-0.950.20.38-0.90.170.130.850.85
0.93-0.810.77-0.50.780.3-0.710.610.25-0.380.780.28-0.22-0.45-0.45
0.88-0.750.77-0.260.970.5-0.980.710.45-0.410.740.48-0.22-0.64-0.64
-0.30.18-0.5-0.26-0.24-0.280.21-0.07-0.33-0.32-0.04-0.27-0.390.050.05
0.83-0.660.780.97-0.240.59-0.970.590.55-0.40.760.57-0.24-0.45-0.45
0.250.150.30.5-0.280.59-0.64-0.260.99-0.23-0.041.0-0.280.280.28
-0.810.62-0.71-0.980.21-0.97-0.64-0.56-0.590.48-0.65-0.620.320.50.5
0.77-0.950.610.71-0.070.59-0.26-0.56-0.31-0.280.85-0.29-0.02-0.94-0.94
0.190.20.250.45-0.330.550.99-0.59-0.31-0.11-0.090.99-0.160.330.33
-0.510.38-0.38-0.41-0.32-0.4-0.230.48-0.28-0.11-0.35-0.220.960.30.3
0.82-0.90.780.74-0.040.76-0.04-0.650.85-0.09-0.35-0.06-0.16-0.64-0.64
0.230.170.280.48-0.270.571.0-0.62-0.290.99-0.22-0.06-0.270.30.3
-0.30.13-0.22-0.22-0.39-0.24-0.280.32-0.02-0.160.96-0.16-0.270.040.04
-0.680.85-0.45-0.640.05-0.450.280.5-0.940.330.3-0.640.30.041.0
-0.680.85-0.45-0.640.05-0.450.280.5-0.940.330.3-0.640.30.041.0
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition

As per the company's disclosures, Unicycive Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Unicycive Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Unicycive Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Unicycive Therapeutics could also be used in its relative valuation, which is a method of valuing Unicycive Therapeutics by comparing valuation metrics of similar companies.
Unicycive Therapeutics is currently under evaluation in z score category among related companies.

Unicycive Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Unicycive Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Unicycive Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Unicycive Therapeutics' value.
Shares
Integrated Wealth Concepts Llc2023-12-31
10 K
Tower Research Capital Llc2023-12-31
6.8 K
Wells Fargo & Co2023-12-31
193
Ubs Group Ag2023-12-31
176
Ground Swell Capital, Llc2023-09-30
0.0
Centiva Capital, Lp2023-09-30
0.0
Beacon Pointe Advisors, Llc2023-12-31
0.0
Two Sigma Advisers, Llc2023-09-30
0.0
Virtu Financial Llc2023-12-31
0.0
Nantahala Capital Management, Llc2023-12-31
6.9 M
Ra Capital Management, Llc2023-12-31
3.5 M

Unicycive Fundamentals

About Unicycive Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Unicycive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unicycive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unicycive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Unicycive Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Unicycive Therapeutics' short interest history, or implied volatility extrapolated from Unicycive Therapeutics options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Unicycive Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Unicycive Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Unicycive Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Unicycive Therapeutics Stock:
Check out Unicycive Therapeutics Piotroski F Score and Unicycive Therapeutics Valuation analysis.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.
Note that the Unicycive Therapeutics information on this page should be used as a complementary analysis to other Unicycive Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Unicycive Stock analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Is Unicycive Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Unicycive Therapeutics. If investors know Unicycive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Unicycive Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.28)
Revenue Per Share
0.028
Return On Assets
(1.53)
Return On Equity
(6.97)
The market value of Unicycive Therapeutics is measured differently than its book value, which is the value of Unicycive that is recorded on the company's balance sheet. Investors also form their own opinion of Unicycive Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Unicycive Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Unicycive Therapeutics' market value can be influenced by many factors that don't directly affect Unicycive Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Unicycive Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Unicycive Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Unicycive Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.